The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHaydale Regulatory News (HAYD)

Share Price Information for Haydale (HAYD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.46
Bid: 0.45
Ask: 0.47
Change: -0.019 (-4.13%)
Spread: 0.02 (4.444%)
Open: 0.46
High: 0.441
Low: 0.441
Prev. Close: 0.46
HAYD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Share Options

26 Apr 2023 15:06

RNS Number : 5832X
Haydale Graphene Industries PLC
26 April 2023
 

 

For immediate release

26 April 2023

 

Haydale Graphene Industries plc

 

("Haydale", "the Company" or the "Group")

 

Grant of share options

 

 

Haydale (AIM: HAYD), the global advanced materials group, announces that on 25 April 2023 the Company approved the following:

 

1. under the 2020 EMI Scheme ("2020 EMI Scheme"), the grant of options to staff of the Group, over an aggregate 1,750,000 ordinary shares of 2p each in the capital of the Company ("Ordinary Shares"); and

2. under the Haydale Technologies, Inc ("HTI") Stock Appreciation Rights Plan 2020 ("2020 SAR"), the grant of stock appreciation rights ("Stock Appreciation Rights") to an employee of the Group's wholly owned US subsidiary, HTI, over an aggregate 1,000,000 Ordinary Shares.

(The 2020 EMI Scheme and the 2020 SAR , together the "Share Schemes". The new Options or Stock Appreciation Rights granted under the Share Schemes, together the "April 2023 Grants"). The April 2023 Grants represents approximately 0.35% of the Company's issued ordinary share capital.

 

Background to the April 2023 Grants

 

The Company adopted the Share Schemes to enable it to retain and incentivise staff and to reward them for the achievement of its longer-term objectives. The Share Schemes have certain performance criteria to ensure that value is created for shareholders before any value is delivered to Directors and key staff. The April 2023 Grants will extend the options to those that have joined since the previous grant of Options in November 2022. 

 

Terms of the April 2023 Grants

 

All of the April 2023 Grants have an exercise price of 2.25p per Ordinary Share (being a 42% premium to the closing mid-market price of the Company's Ordinary Shares on 25 April 2023, (the day of the approval of the April 2023 Grants) and can only be exercised between the third and tenth anniversary of the awards. The proportion of the awards made by the April 2023 Grants that are capable of vesting is dependent on certain performance criteria, directly linked to the performance of the Company's share price over the period to 30 September 2026 as follows:

 

% of April 2023 Grants subject to the Performance Condition

 

Performance Condition

 

30%

For a period of 15 consecutive dealing days, commencing after the date of the April 2023 Grants and ending on or before the 30 September 2024, the closing price of the Ordinary Shares exceeds 4p (four) per Ordinary Share.

 

30%

For a period of 15 consecutive dealing days, commencing after the date of the April 2023 Grants and ending on or before the 30 September 2025, the closing price of the Ordinary Shares exceeds 6p (six) per Ordinary Share.

 

40%

For a period of 15 consecutive dealing days, commencing after the date of the April 2023 Grants and ending on or before the 30 September 2026, the closing price of the Ordinary Shares exceeds 8p (eight) per Ordinary Share.

 

There are no other vesting criteria for the April 2023 Grants. If the share price does not reach the target price by their respective dates, that portion of the award will lapse.

 

The Company's Remuneration Committee retains the ability to amend the performance conditions for the April 2023 Grants and for future grants to ensure that such grants achieve the stated purpose.

 

Following the April 2023 Grants, the Company's total number of Options and SARs outstanding as at the date of this announcement is 101,775,000 representing approximately 12.95% of the Company's existing issued share capital and 9.90% on a fully diluted basis including all outstanding warrants.

 

The number of Ordinary Shares currently in issue is 785,852,475 and it is this number that has been used to calculate the above percentage shareholdings.

 

 

For further information:

Haydale Graphene Industries plc

David Banks, Non-Executive Chair

Tel: +44 (0) 1269 842 946

 

www.haydale.com 

finnCap (Nominated Adviser & Broker)

 

Julian Blunt/Edward Whiley, Corporate Finance

Andrew Burdis, ECM

Tel: +44 (0) 20 7220 0500 

 

 

Notes to Editors

 

Haydale is a global technologies and materials group that facilitates the integration of graphene and other nanomaterials into the next generation of commercial technologies and industrial materials. With expertise in graphene, silicon carbide and other nanomaterials, Haydale is able to deliver improvements in electrical, thermal and mechanical properties, as well as toughness. Haydale has granted patents for its technologies in Europe, USA, Australia, Japan and China and operates from six sites in the UK, USA and the Far East.

 

For more information please visit: www.haydale.com

Twitter: @haydalegraphene

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHNKABKQBKDQQB
Date   Source Headline
13th Jun 20189:00 amRNSPrice Monitoring Extension
13th Jun 20187:00 amRNSTrading Statement and Director Resignation
25th May 20187:00 amRNSHaydale Ceramics Technologies
16th Apr 20189:10 amRNSNotification of Major Holdings
1st Mar 20187:00 amRNSInterim Results
19th Feb 20187:00 amRNSSupply Agreement with Graphene Platform Corp
25th Jan 20187:00 amRNSTrading Update
18th Jan 20187:00 amRNSChange of Adviser
17th Jan 20187:00 amRNSCommercial Agreement with Talga Resources
18th Dec 20177:00 amRNSShare options and awards, LTIP and PDMR dealings
12th Dec 201711:25 amRNSResult of AGM
20th Nov 20177:00 amRNSNew Patent Application
20th Nov 20177:00 amRNSAnnual Report & Notice of AGM
1st Nov 20177:00 amRNSPDMR Dealings
31st Oct 20175:48 pmRNSNotification of Major Holdings
30th Oct 20177:00 amRNSGrant of US Patent
27th Oct 201710:45 amRNSResult of General Meeting, Issue of Equity and TVR
26th Oct 201710:06 amRNSResult of Conditional Offer
19th Oct 20171:20 pmRNSCREST Clarification
10th Oct 20174:21 pmRNSClose of Accelerated Bookbuild
10th Oct 20177:00 amRNSProposed Accelerated Bookbuild to raise £6 million
10th Oct 20177:00 amRNSFull Year Results
26th Sep 20177:00 amRNSEverpower places initial orders for Chinese market
11th Sep 20177:00 amRNSChange of Adviser
1st Sep 20177:00 amRNSNew Sales Contract
22nd Aug 20177:00 amRNSAdvanced Composites Proposed Collaboration
9th Aug 20177:00 amRNSLaunch of Taiwan operations
19th Jul 20177:00 amRNSTrading update
13th Jul 20177:00 amRNSAppointment of Chairman
29th Jun 20177:00 amRNSGrant of Options
20th Jun 20177:00 amRNSIssue of Equity and Total Voting Rights
24th May 201711:30 amRNSPDMR Dealing
15th May 20177:00 amRNSAcquisition of HTI Minority Interest
11th May 20177:00 amRNSMemorandum of Understanding with Nanospan India
9th May 20177:00 amRNSIssue of Equity and Total Voting Rights
28th Apr 20177:00 amRNSIssue of Shares
25th Apr 20177:00 amRNSPDMR Dealing
19th Apr 20177:00 amRNSPDMR Dealing
10th Apr 20177:00 amRNSIssue of Equity and Total Voting Rights
10th Apr 20177:00 amRNSIssue of Shares
31st Mar 20174:00 pmRNSIssue of Equity and Total Voting Rights
31st Mar 20177:00 amRNSIssue of Shares
27th Mar 20175:05 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
22nd Mar 20177:00 amRNSInterim Results
15th Mar 20177:00 amRNSFour-year supply agreement
7th Mar 20177:00 amRNSIssue of Shares
20th Feb 20177:00 amRNSIssue of Shares
3rd Feb 20177:01 amRNSProposed Strategic Investment
3rd Feb 20177:00 amRNSTrading update & Notice of results
16th Jan 201711:45 amRNSDirector Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.